BioRestorative Therapies Announces Strategic Partnership with Global Dermatology Leader Dr. David J. Goldberg to Lead Clinical Evaluation and Seek Multi-Channel Adoption of Its Regenerative BioCosmeceutical Platform

Collaboration establishes an independent clinical validation pathway, expands access to influential physician networks, and strengthens the foundation for possible broad commercial growth across professional, biologic dermal, and consumer channels

MELVILLE, N.Y., April 21, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative," "BRTX," or the "Company") (Nasdaq: BRTX), a late-stage clinical regenerative medicine company focused on stem cell-based therapies and products, today announced a strategic partnership with David J. Goldberg, M.D., J.D., internationally recognized as one of the foremost innovators in laser dermatology, regenerative aesthetics, and clinical research leadership. Through the agreement, the Company is seeking to accelerate both scientific validation and market adoption of its regenerative BioCosmeceutical platform across the Company's expanding commercial ecosystem.

As part of this collaboration, the Company intends for Dr. Goldberg to lead a prospective, controlled human clinical study designed to generate comparative outcome data evaluating improvements in skin appearance, texture, and overall quality relative to current aesthetic treatment benchmarks. The study is intended to be conducted using BioRestorative's secretome-derived biologics - enriched with exosomes, growth factors, cytokines, and peptides - manufactured in the Company's cGMP, ISO-7-certified cleanroom facility. Results are expected to support publication-quality evidence that further defines the platform's clinical role across professional and consumer applications.

"Dr. Goldberg's involvement materially strengthens both the scientific and commercial trajectory of our BioCosmeceutical platform," said Lance Alstodt, BioRestorative Therapies President, Chief Executive Officer and Chairman. "Our products are designed for use across professional, biologic dermal retail, and direct-to-consumer settings, and in each of those markets, independent clinical validation by a physician of his caliber is a meaningful differentiator. Just as importantly, his engagement opens direct access to physician networks and industry forums that drive adoption in regenerative aesthetics. The data generated through this study will directly support how we position, educate, and expand adoption of our products across every segment of our go-to-market strategy."

Schreibe Deinen Kommentar